Holen Sie sich die Stockscreener-App
1.1473
2.44%
0.0273
Schlusskurs vom Vortag:
$1.12
Offen:
$1.14
24-Stunden-Volumen:
340.45K
Relative Volume:
0.17
Marktkapitalisierung:
$191.44M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.6953
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-1.94%
1M Leistung:
-5.18%
6M Leistung:
-30.47%
1J Leistung:
-64.81%
1-Tages-Spanne:
$1.10
$1.16
1-Wochen-Bereich:
$1.025
$1.20
52-Wochen-Spanne:
$0.6611
$5.92
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Vergleichen Sie FATE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.1473 | 191.44M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.12 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.51 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.72 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.77 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan
Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel
ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Fate Therapeutics Appoints Matthew Abernethy to Board of Directors, Timothy P. Coughlin Steps Down - Nasdaq
Fate Therapeutics appoints new board member - Investing.com
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors - GlobeNewswire
Fate Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Fate Therapeutics to present lupus treatment data at EULAR 2025 By Investing.com - Investing.com South Africa
Fate Therapeutics to present lupus treatment data at EULAR 2025 - Investing.com Australia
Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases - Insider Monkey
Prime Mining: Expanding a High-Grade Gold and Silver Resource in Mexico - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - The Manila Times
Viridian Metals: Targeting Critical Copper Discoveries in Newfoundland - The Globe and Mail
Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress - GlobeNewswire Inc.
Northern Trust Corp Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Canada
Fate Therapeutics’ SWOT analysis: stock outlook amid clinical progress - Investing.com
BNP Paribas Financial Markets Raises Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics Reports Q1 2025 Financial Results - TipRanks
Price T Rowe Associates Inc. MD Cuts Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
StockNews.com Upgrades Fate Therapeutics (NASDAQ:FATE) to Hold - Defense World
Barclays Cuts Fate Therapeutics (NASDAQ:FATE) Price Target to $2.00 - Defense World
Wedbush Predicts Increased Earnings for Fate Therapeutics - Defense World
What is Leerink Partnrs’ Estimate for FATE Q2 Earnings? - Defense World
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus - MSN
Needham & Company LLC Reiterates “Hold” Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bressi Jerome Charles | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,980 |
9,269 |
270,203 |
| TAHL CINDY | See Remarks |
Jan 10 '25 |
Sale |
1.55 |
5,654 |
8,764 |
336,707 |
| Valamehr Bahram | President and CEO |
Jan 10 '25 |
Sale |
1.54 |
8,705 |
13,406 |
349,364 |
0.17%
1.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):